The objectives of the Protocol Review and Monitoring System (PRMS) are to implement a transdisciplinary scientific peer-review system that ensures internal oversight of the scientific quality and progress of clinical trials and optimally engages the institution's resources. The system ensures that clinical research trials at the USC Norris Comprehensive Cancer Center (NCCC) are of the highest scientific quality and integrity by review of the scientific merit, priorities and progress.
The specific aims of the PRMS are to: 1) maintain a Clinical Investigation Committee (CIC) with sufficient breadth of expertise to conduct an objective scientific and operational review of all clinical cancer research protocols;2) facilitate prompt initiation of approved protocols by interfacing with the IRB to ensure compliance with local and federal regulations;3) ensure and oversee a system of prioritization of clinical research protocols;4) monitor the scientific progress of clinical research protocols and ensure closure as required by interim analysis and stopping rules;5) terminate clinical research protocols that fail to meet expectations for scientific progress;6) review amendments for ongoing clinical research protocols;and 7) monitor compliance as well as gender and minority accrual in the conduct of clinical research protocols. The CIC is assisted by the Quality Assurance and Monitoring Committee (QAMC) in the monitoring of the progress of the studies. The QAMC fulfills multiple functions as detailed in the CISO section of the grant. In regards to PRMS, it provides the essential data regarding accrual and study conduct to the CIC, which allows the latter to perform its progress monitoring functions optimally.
As mandated by the Cancer Center, the Clinical Investigations Support Office provides essential assistance and support to investigators through the CIC and through the QAMC in order to ensure scientific quality and integrity starting with the initiation of each study and continuing to study completion.
|Neumeyer, Sonja; Banbury, Barbara L; Arndt, Volker et al. (2018) Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer. Br J Cancer 118:1639-1647|
|Basso, Virginia; Garcia, Angie; Tran, Dat Q et al. (2018) Fungicidal Potency and Mechanisms of ?-Defensins against Multidrug-Resistant Candida Species. Antimicrob Agents Chemother 62:|
|Austria, Theresa; Marion, Christine; Yu, Vanessa et al. (2018) Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways. Int J Cancer 143:2932-2942|
|Ning, Y; Zhang, W; Hanna, D L et al. (2018) Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients. Pharmacogenomics J 18:29-34|
|Battaglin, Francesca; Naseem, Madiha; Puccini, Alberto et al. (2018) Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell Int 18:99|
|Zhang, Junjie; Zhao, Jun; Xu, Simin et al. (2018) Species-Specific Deamidation of cGAS by Herpes Simplex Virus UL37 Protein Facilitates Viral Replication. Cell Host Microbe 24:234-248.e5|
|Eriguchi, Yoshihiro; Nakamura, Kiminori; Yokoi, Yuki et al. (2018) Essential role of IFN-? in T cell-associated intestinal inflammation. JCI Insight 3:|
|Thomas, Nancy E; Edmiston, Sharon N; Orlow, Irene et al. (2018) Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes. J Invest Dermatol 138:2398-2404|
|Cobo, Eduardo R; Holani, Ravi; Moreau, France et al. (2018) Entamoeba histolytica Alters ileal Paneth Cell Functions in Intact and Muc2 Mucin Deficiency. Infect Immun :|
|Suenaga, Mitsukuni; Schirripa, Marta; Cao, Shu et al. (2018) Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Clin Colorectal Cancer 17:e395-e414|
Showing the most recent 10 out of 842 publications